Fedorenko Victor, Genilloud Olga, Horbal Liliya, Marcone Giorgia Letizia, Marinelli Flavia, Paitan Yossi, Ron Eliora Z
Department of Genetics and Biotechnology, Ivan Franko National University of Lviv, Lviv 79005, Ukraine.
Fundación MEDINA, Health Sciences Technology Park, 18016 Granada, Spain.
Biomed Res Int. 2015;2015:591349. doi: 10.1155/2015/591349. Epub 2015 Aug 3.
Concern over the reports of antibiotic-resistant bacterial infections in hospitals and in the community has been publicized in the media, accompanied by comments on the risk that we may soon run out of antibiotics as a way to control infectious disease. Infections caused by Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Clostridium difficile, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and other Enterobacteriaceae species represent a major public health burden. Despite the pharmaceutical sector's lack of interest in the topic in the last decade, microbial natural products continue to represent one of the most interesting sources for discovering and developing novel antibacterials. Research in microbial natural product screening and development is currently benefiting from progress that has been made in other related fields (microbial ecology, analytical chemistry, genomics, molecular biology, and synthetic biology). In this paper, we review how novel and classical approaches can be integrated in the current processes for microbial product screening, fermentation, and strain improvement.
医院和社区中耐抗生素细菌感染的报道引发了媒体的关注,同时也伴随着关于我们可能很快耗尽抗生素作为控制传染病手段的风险的评论。由粪肠球菌、金黄色葡萄球菌、克雷伯菌属、艰难梭菌、鲍曼不动杆菌、铜绿假单胞菌、大肠杆菌和其他肠杆菌科细菌引起的感染构成了重大的公共卫生负担。尽管制药行业在过去十年对该主题缺乏兴趣,但微生物天然产物仍然是发现和开发新型抗菌药物最具吸引力的来源之一。微生物天然产物筛选和开发的研究目前受益于其他相关领域(微生物生态学、分析化学、基因组学、分子生物学和合成生物学)所取得的进展。在本文中,我们综述了如何将新颖和经典方法整合到当前微生物产物筛选、发酵及菌株改良的流程中。